These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 31517707)

  • 1. A history of prophylaxis in haemophilia.
    Moreno MM; Cuesta-Barriuso R
    Blood Coagul Fibrinolysis; 2019 Sep; 30(1S Suppl 1):S1-S3. PubMed ID: 31517707
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A history of prophylaxis in haemophilia.
    Moreno MM; Cuesta-Barriuso R
    Blood Coagul Fibrinolysis; 2019 Mar; 30(2):55-57. PubMed ID: 30507712
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Limitations of prophylactic treatment in patients with hemophilia.
    López Fernández MF
    Blood Coagul Fibrinolysis; 2019 Sep; 30(1S Suppl 1):S22-S24. PubMed ID: 31157677
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Prevention of joint damage in hemophilic children with early prophylaxis].
    Kreuz W; Escuriola Ettingshausen C; Funk M; Pons S; Schmidt H; Kornhuber B
    Orthopade; 1999 Apr; 28(4):341-6. PubMed ID: 10335528
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Review of antihemophilic factor injection for the routine prophylaxis of bleeding episodes and risk of joint damage in severe hemophilia A.
    Rossbach HC
    Vasc Health Risk Manag; 2010 Mar; 6():59-68. PubMed ID: 20234780
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Forum on: the role of recombinant factor VIII in children with severe haemophilia A.
    Franchini M; Coppola A; Molinari AC; Santoro C; Schinco P; Speciale V; Tagliaferri A
    Haemophilia; 2009 Mar; 15(2):578-86. PubMed ID: 19187188
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prophylaxis for severe haemophilia: clinical challenges in the absence as well as in the presence of inhibitors.
    Fischer K; Valentino L; Ljung R; Blanchette V
    Haemophilia; 2008 Jul; 14 Suppl 3():196-201. PubMed ID: 18510542
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prophylaxis for severe haemophilia: clinical and economical issues.
    Fischer K; Van Den Berg M
    Haemophilia; 2003 Jul; 9(4):376-81. PubMed ID: 12828671
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clotting factor concentrates given to prevent bleeding and bleeding-related complications in people with hemophilia A or B.
    Iorio A; Marchesini E; Marcucci M; Stobart K; Chan AK
    Cochrane Database Syst Rev; 2011 Sep; (9):CD003429. PubMed ID: 21901684
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The treatment of haemophilia, including prophylaxis, constant infusion and DDAVP.
    Berntorp E
    Baillieres Clin Haematol; 1996 Jun; 9(2):259-71. PubMed ID: 8800504
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of prophylactic treatment regimens in children with severe haemophilia: a comparison of different strategies.
    van den Berg HM; Fischer K; van der Bom JG; Roosendaal G; Mauser-Bunschoten EP
    Haemophilia; 2002 Mar; 8 Suppl 2():43-6. PubMed ID: 11966853
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia.
    Manco-Johnson MJ; Abshire TC; Shapiro AD; Riske B; Hacker MR; Kilcoyne R; Ingram JD; Manco-Johnson ML; Funk S; Jacobson L; Valentino LA; Hoots WK; Buchanan GR; DiMichele D; Recht M; Brown D; Leissinger C; Bleak S; Cohen A; Mathew P; Matsunaga A; Medeiros D; Nugent D; Thomas GA; Thompson AA; McRedmond K; Soucie JM; Austin H; Evatt BL
    N Engl J Med; 2007 Aug; 357(6):535-44. PubMed ID: 17687129
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Personalized prophylaxis in people with hemophilia A: challenges and achievements.
    Ar MC; Baslar Z; Soysal T
    Expert Rev Hematol; 2016 Dec; 9(12):1203-1208. PubMed ID: 27809624
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term outcome of individualized prophylactic treatment of children with severe haemophilia.
    van den Berg HM; Fischer K; Mauser-Bunschoten EP; Beek FJ; Roosendaal G; van der Bom JG; Nieuwenhuis HK
    Br J Haematol; 2001 Mar; 112(3):561-5. PubMed ID: 11260054
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discontinuing early prophylaxis in severe haemophilia leads to deterioration of joint status despite low bleeding rates.
    Nijdam A; Foppen W; De Kleijn P; Mauser-Bunschoten EP; Roosendaal G; van Galen KP; Schutgens RE; van der Schouw YT; Fischer K
    Thromb Haemost; 2016 May; 115(5):931-8. PubMed ID: 26791021
    [TBL] [Abstract][Full Text] [Related]  

  • 16. When should prophylactic treatment in patients with haemophilia A and B start?--The German experience.
    Kreuz W; Escuriola-Ettingshausen C; Funk M; Schmidt H; Kornhuber B
    Haemophilia; 1998 Jul; 4(4):413-7. PubMed ID: 9873763
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prospective controlled studies on prophylaxis: an Italian approach.
    Gringeri A
    Haemophilia; 2003 May; 9 Suppl 1():38-42; discussion 43. PubMed ID: 12709036
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Orthopaedic evaluation in children with severe haemophilia A or B submitted to primary prophylaxis therapy in a coagulopathy treatment centre.
    De Podestá Haje D; Ono F; De Oliveira GB; Almeida J; De Paula JC; Batista Neto LV; Silva Barros SB
    Haemophilia; 2011 Mar; 17(2):228-32. PubMed ID: 21070500
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clotting factor concentrates given to prevent bleeding and bleeding-related complications in people with hemophilia A or B.
    Stobart K; Iorio A; Wu JK
    Cochrane Database Syst Rev; 2005 Apr; (2):CD003429. PubMed ID: 15846666
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prevention of arthropathy in haemophilia: prophylaxis.
    Santagostino E; Mancuso ME
    Haemophilia; 2008 Nov; 14 Suppl 6():16-9. PubMed ID: 19134028
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.